Denovo Biopharma is a privately held biotech company specializing in personalized medicine through innovative biomarker solutions. Operating in the pharmaceutical and biotechnology sectors, Denovo Biopharma serves biotech and pharmaceutical companies by providing a unique platform for de novo genomic biomarker discovery. This technology is particularly valuable for late-stage clinical drugs that have shown unsatisfactory efficacy in trials. By identifying biomarkers that correlate with patient responsiveness to drug candidates, Denovo Biopharma enables more targeted and cost-effective clinical trials. The company's core technology uses archived clinical samples to discover biomarkers retrospectively, which can be applied across various therapeutic areas including oncology, metabolic disorders, cardiology, immunology, and neurology. Denovo Biopharma generates revenue by partnering with biotech and pharmaceutical companies to enhance their drug development processes, thereby increasing the likelihood of successful clinical outcomes.

Keywords: biomarker discovery, personalized medicine, genomic platform, clinical trials, oncology, cardiology, immunology, neurology, drug development, biotech partnerships.